SCHEMBL9877242

SCHEMBL9877242

Cc1cc(O)c(C(C)C)cc1N=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.62
▸ HTT P42858 2/20 0.62
▸ MAPT P10636 5/20 0.56
▸ PKM P14618 4/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ CYP1A2 P05177 3/20 0.56
▸ CYP2D6 P10635 3/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ CYP2C9 P11712 2/20 0.56
▸ ALOX15 P16050 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ HIF1A Q16665 2/20 0.56
▸ THRB P10828 1/20 0.56
▸ MEN1 O00255 2/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.54
▸ G6PD P11413 3/20 0.52
▸ ALDH1A1 P00352 5/20 0.51
▸ GAA P10253 3/20 0.51
▸ HPGD P15428 1/20 0.51
▸ ADORA2A P29274 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21686456 0.84 LMNA (0.47) LMNAHTTMAPTPKMKMT2A
SCHEMBL1274931 0.82 LMNA (0.62) LMNAHTTMAPTPKMKMT2A
SCHEMBL18072576 0.79 HTT (0.44) LMNAHTTMAPTPKMKMT2A
SCHEMBL30903400 0.77 MAPT (0.48) LMNAHTTMAPTPKMKMT2A
SCHEMBL9464262 0.77 MAPT (0.48) LMNAHTTMAPTPKMKMT2A
SCHEMBL10705862 0.77 LMNA (0.49) LMNAHTTMAPTPKMKMT2A
SCHEMBL29872559 0.77 LMNA (0.68) LMNAHTTMAPTPKMKMT2A
SCHEMBL214157 0.77 LMNA (0.68) LMNAHTTMAPTPKMKMT2A
SCHEMBL14102261 0.77 MAPT (0.49) LMNAHTTMAPTPKMKMT2A
SCHEMBL5695128 0.76 LMNA (0.47) LMNAHTTMAPTPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-57098245-A — — None — — JP disclosed
US-12545896-B2 Growth inhibitor Orizuru Therapeutics, Inc. (JP) 2026-02-10 — — US disclosed
US-12295955-B2 TTP phosphorylation for the identification of personalized medicines KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2025-05-13 — — US disclosed
CN-114929854-B Proliferation inhibitors 千纸鹤治疗公司 2025-05-02 — — CN disclosed
EP-4479042-A1 CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-12-25 — — EP disclosed
US-20240390406-A1 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2024-11-28 — — US disclosed
EP-4467978-A1 PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS King Faisal Specialist Hospital & Research Centre (SA) 2024-11-27 — — EP disclosed
CN-111051468-B Homogeneous anaerobically stable quantum dot concentrates 昭荣化学工业株式会社 2024-06-04 — — CN disclosed
US-20240124846-A1 GROWTH INHIBITOR Orizuru Therapeutics, Inc. (JP) 2024-04-18 — — US disclosed
US-20230310437-A1 TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) 2023-10-05 — — US disclosed
WO-2021079874-A1 PROLIFERATION INHIBITOR 武田薬品工業株式会社 2021-04-29 — — WO disclosed
US-10919770-B2 Homogeneous anaerobically stable quantum dot concentrates NANOSYS, INC. (US) 2021-02-16 — — US disclosed
CN-111051468-A Homogeneous anaerobically stable quantum dot concentrates 纳米系统公司 2020-04-21 — — CN disclosed
WO-2018237236-A1 HOMOGENEOUS ANAEROBICALLY STABLE QUANTUM DOT CONCENTRATES SMITH AUSTIN (US) 2018-12-27 — — WO disclosed
US-20180370800-A1 HOMOGENEOUS ANAEROBICALLY STABLE QUANTUM DOT CONCENTRATES NANOSYS, INC. (US) 2018-12-27 — — US disclosed
CN-103045149-B Heat vulcanization adhesive for bonding vulcanized rubber or thermoplastic rubber with hard panel SHANGHAI POLYTON NEW MATERIAL TECHNOLOGY CO LTD 2014-03-05 — — CN disclosed
US-5001171-A Process, modified rubbers and rubber compositions BRIDGESTONE/FIRESTONE, INC. (US) 1991-03-19 — — US disclosed
EP-0319733-A2 Process, modified rubbers and rubber compositions THE FIRESTONE TIRE & RUBBER COMPANY (US) 1989-06-14 — — EP disclosed
US-4788229-A BLENDING MIXTURES OF UNCURED ELASTOMERS AND FILLERS CONTAINING ELASTOMER-FILLER LINKAGE PROMOTERS; TIRES; FRICTION RESISTANCE; REDUCED HYSTERESIS THE FIRESTONE TIRE & RUBBER COMPANY (US) 1988-11-29 — — US disclosed
JP-S5798245-A PREPARATION OF P-ACETAMIDOTHYMOL FUJIREBIO INC 1982-06-18 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545896-B2 Growth inhibitor IAPP, PLK4, IGF1R LMNA 3142/4885HTT 2954/4885MAPT 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback